Antithrombotic Management in Patients With Atrial Fibrillation Following Percutaneous Coronary Intervention: An...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Atrial fibrillation (AF) patients frequently experience acute coronary syndrome (ACS) and require percutaneous coronary intervention (PCI).
• Both ACS and PCI necessitate dual antiplatelet therapy (DAPT), while AF management requires oral anticoagulation (OAC) to prevent thromboembolism.
• Combining these therapies presents a complex clinical challenge due to increased risks of bleeding and thrombosis.

Purpose of the Study:

• To review current evidence on antithrombotic strategies for patients with AF undergoing PCI.
• To explore the complexities of balancing antithrombotic therapy to mitigate both bleeding and thrombotic events.
• To summarize therapeutic options beyond traditional triple therapy.

Main Methods:

• This is a narrative review article.
• The review synthesizes existing clinical evidence on antithrombotic treatments.
• Focus is on patients with both AF and a history of PCI.

Main Results:

• Triple therapy (OAC plus DAPT) is a common initial strategy for AF patients undergoing PCI.
• Less intensive antithrombotic regimens may reduce bleeding events.
• Evidence suggests that reduced intensity therapies might not increase thrombotic risk.

Conclusions:

• Antithrombotic therapy in AF patients undergoing PCI requires careful consideration of individual risk factors.
• Less intensive regimens warrant further investigation as potentially safer alternatives to triple therapy.
• Optimizing antithrombotic treatment is crucial for improving outcomes in this high-risk patient population.